AMPD1 polymorphism and response to regadenoson

Rayan Saab, Aline N. Zouk, Ronald Mastouri, Todd Skaar, Santosh Philips, Rolf Kreutz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. Subjects & methods: Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. Results: Carriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p = 0.01) ([%] SBP change to nadir:-3 ± 15 vs-7 ± 11%; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04). Conclusion: AMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.

Original languageEnglish (US)
Pages (from-to)1807-1815
Number of pages9
JournalPharmacogenomics
Volume16
Issue number16
DOIs
StatePublished - Nov 1 2015

Fingerprint

Blood Pressure
regadenoson
Heart Rate
Hemodynamics

Keywords

  • adenosine
  • genetic
  • myocardial perfusion imaging
  • regadenoson

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

AMPD1 polymorphism and response to regadenoson. / Saab, Rayan; Zouk, Aline N.; Mastouri, Ronald; Skaar, Todd; Philips, Santosh; Kreutz, Rolf.

In: Pharmacogenomics, Vol. 16, No. 16, 01.11.2015, p. 1807-1815.

Research output: Contribution to journalArticle

Saab, Rayan ; Zouk, Aline N. ; Mastouri, Ronald ; Skaar, Todd ; Philips, Santosh ; Kreutz, Rolf. / AMPD1 polymorphism and response to regadenoson. In: Pharmacogenomics. 2015 ; Vol. 16, No. 16. pp. 1807-1815.
@article{e492e4e282814aba908b223bbbbfb2e6,
title = "AMPD1 polymorphism and response to regadenoson",
abstract = "Aims: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. Subjects & methods: Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. Results: Carriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([{\%}] SBP change to peak: 12 ± 25 vs 5 ± 13{\%}; p = 0.01) ([{\%}] SBP change to nadir:-3 ± 15 vs-7 ± 11{\%}; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04). Conclusion: AMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.",
keywords = "adenosine, genetic, myocardial perfusion imaging, regadenoson",
author = "Rayan Saab and Zouk, {Aline N.} and Ronald Mastouri and Todd Skaar and Santosh Philips and Rolf Kreutz",
year = "2015",
month = "11",
day = "1",
doi = "10.2217/pgs.15.116",
language = "English (US)",
volume = "16",
pages = "1807--1815",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "16",

}

TY - JOUR

T1 - AMPD1 polymorphism and response to regadenoson

AU - Saab, Rayan

AU - Zouk, Aline N.

AU - Mastouri, Ronald

AU - Skaar, Todd

AU - Philips, Santosh

AU - Kreutz, Rolf

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Aims: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. Subjects & methods: Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. Results: Carriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p = 0.01) ([%] SBP change to nadir:-3 ± 15 vs-7 ± 11%; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04). Conclusion: AMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.

AB - Aims: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. Subjects & methods: Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. Results: Carriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p = 0.01) ([%] SBP change to nadir:-3 ± 15 vs-7 ± 11%; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04). Conclusion: AMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.

KW - adenosine

KW - genetic

KW - myocardial perfusion imaging

KW - regadenoson

UR - http://www.scopus.com/inward/record.url?scp=84947909228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947909228&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.116

DO - 10.2217/pgs.15.116

M3 - Article

VL - 16

SP - 1807

EP - 1815

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 16

ER -